Recent advances in irreversible kinase inhibitors.
In Pharm Pat Anal, Jul 2014
The patent literature from 2010 to 2013 has been reviewed and novel irreversible kinase inhibitors for Bruton's tyrosine kinase, epidermal growth factor receptor, Janus kinase 3, phosphoinsitide 3 and other kinases are disclosed and discussed.
Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
London, United Kingdom. In Drugs Today (barc), Jul 2014
Imbruvica (ibrutinib), an oral first-in-class Bruton's tyrosine kinase inhibitor, recently entered the market following accelerated approval in the relapsed/refractory setting, but long-term survival data are currently immature.
[Kinase inhibitors against hematological malignancies].
In Nihon Rinsho, Jun 2014
As for AML and lymphoid malignancies, many kinase inhibitors targeting FLT3, BTK and aurora-A are on early and late clinical trials, and a number of promising drugs including ibrutinib are picked up for further evaluation.